National Neuroscience Institute   Report issue

Government Phase 2 Phase 4
Founded: Singapore (1999)

Organization Overview

First Clinical Trial
2006
NCT00669344
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

National Neuroscience Institute | National Neuroscience Institute - Tan Tock Seng campus and Changi hospital

Active Ingredients

Drugs in Phase 4 Trials (2)

minocycline (minocin) (1 trial)

rivastigmine (exelon) (2 trials)

Drugs in Phase 2 Trials (4)

ac-vsrrr-nh2 (1 trial)

gingko biloba (1 trial)

sodium chloride (1 trial)

tocotrienol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 4)

Cerebral Hemorrhage (Phase 2)

Cerebrovascular Disorders (Phase 2)

Cognitive Dysfunction (Phase 4)

Hemorrhage (Phase 2)

Stroke (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 6